SBIR-STTR Award

Tape Mechanical Occlusive Device (TMOD)
Award last edited on: 7/3/12

Sponsored Program
SBIR
Awarding Agency
NIH : NIDDK
Total Award Amount
$1,498,749
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Gerald W Timm

Company Information

GT Urological LLC (AKA: Novatek Medical Inc)

960 East Hennepin Avenue
Minneapolis, MN 55414
   (612) 379-3578
   info@gturo.com
   www.gturological.com
Location: Single
Congr. District: 05
County: Hennepin

Phase I

Contract Number: 1R43DK076397-01A1
Start Date: 9/30/06    Completed: 9/29/07
Phase I year
2006
Phase I Amount
$460,767
GT Urological, LLC has prepared this NIH SBIR Phase I grant application entitled "Tape Mechanical Occlusive Device (TMOD)" to detail goals and activities related to the design and development of a totally implantable, mechanically actuated urethral occlusive device intended to safely and effectively prevent urinary leakage in males suffering from Stress Urinary Incontinence (SUI). SUI frequently occurs in males who have undergone surgery to remove their cancerous prostates. TMOD offers significant advantages over existing urinary incontinence treatments that impart a permanent partial obstruction to voiding or require extensive surgery such as bulking agents, urethral slings and hydraulic cuffs. These advantages include 1) one piece design intended to reduce intra- operative device assembly, 2) simplification and shortening of surgical procedure, 3) implantation through a single incision, 4) reduced urethral atrophy and erosion, 5) on- demand control of a patient's incontinence, 6) occlusion to urethral/bladder/neck circumferences lower than 2.5 cm and 7) a minimally invasive procedure to readjust degree of continence should surgery not have provided a satisfactory outcome. The TMOD project begins with a tooling phase to further develop a prototype design followed by manufacturing builds. Ethylene Oxide sterilization processes will be validated during the course of the grant and used to sterilize TMOD devices in preparation for biocompatibility testing and verification & validation testing which includes chronic animal implantation. TMOD specifications will be created in accordance with GT Urological, LLC Quality System Procedures and testing will be performed to insure the device's adherence to functional and performance specifications. Fixturing will be identified and built to automate testing requiring great numbers of performance or functional cycles. Sterilized devices will be implanted chronically in (3) female mongrel dogs to assess 1) ability to activate/deactivate the device following capsular formation, 2) ability to maintain bladder neck occlusive pressures and 3) potential for bladder neck erosion and tissue damage. Following completion of these design and development steps, an Investigational Device Exemption (IDE) submission to the FDA will be made to allow human clinical trials to begin. Tape Mechanical Occlusive Device (TMOD) Project Narrative The Tape Mechanical Occlusive Device (TMOD) is intended to provide relief to an estimated 6 million US men suffering from stress and mixed urinary incontinence. The TMOD is intended to provide functional and surgical advantages over current technologies used for the treatment of stress and mixed urinary incontinence.

Thesaurus Terms:
Biomedical Equipment Development, Implant, Urethra, Urinary Incontinence Antiseptic Sterilization, Biomaterial Compatibility, Ethylene Oxide, Injection /Infusion, Temperature Dog, Medical Implant Science

Phase II

Contract Number: 2R44DK076397-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2008
(last award dollars: 2011)
Phase II Amount
$1,037,982

The purpose of this Phase II SBIR proposal is to optimize the design of the Tape Mechanical Occlusive Device (TMOD) in a 10 patient Phase II Clinical Trial in men with stress urinary incontinence. The feasibility for using this device in a safe and effective manner in humans was demonstrated by bench testing, cadaveric sizing, positioning and occlusion measurements and in animal implants in the Phase I SBIR study. The proposed human study will afford the opportunity to each of the 10 subjects to evaluate and report on efficacy and ease of use. At the conclusion of this Phase II Clinical Trial we anticipate entering into a Phase III Clinical Trial to gain sufficient experience with the TMOD design to submit a Pre- Market Approval Application to the Food and Drug Administration to permit full commercialization of this device. The team assembled to conduct this trial has extensive experience with the development and commercialization of urologic implants. The team and consultants believe that this technology offers significant competitive advantages over existing implantable devices for managing male urinary incontinence, a market that currently exceeds $50 million in annual sales and could also help reduce the multi-billion dollar cost of managing patients with absorbency products.

Public Health Relevance:
The Tape Mechanical Occlusive Device (TMOD) is intended to provide relief to an estimated 6 million US men suffering from stress and mixed urinary incontinence. The TMOD is intended to provide functional and surgical advantages over current technologies used for the treatment of stress and mixed urinary incontinence.

Public Health Relevance:
Tape Mechanical Occlusive Device (TMOD) Project Narrative The Tape Mechanical Occlusive Device (TMOD) is intended to provide relief to an estimated 6 million US men suffering from stress and mixed urinary incontinence. The TMOD is intended to provide functional and surgical advantages over current technologies used for the treatment of stress and mixed urinary incontinence.

Thesaurus Terms:
There Are No Thesaurus Terms On File For This Project.